Figure 4From: A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In VivoCLL mouse model. (A) CLL PBMCs from two patients were labeled with CFSE and randomized among the groups. The 108 CFSE-labeled cells were injected intravenously into NSG mice (lacking T, B and NK cells). Groups of five mice received daily dosing of saline: NXT629 at 30 mg/kg IP or fludarabine at 50 mg/kg IP. Mice were killed 4 wks after engraftments, and the splenocytes were stained with hCD19 and analyzed by flow cytometry. Data are hCD19+/CFSE+ cells normalized to vehicle control. (B) Proliferative model. Groups of mice received daily dosing of saline, NXT629 at 30 mg/kg IP. Mice were killed 2 wks after engraftments of CLL cells. CLL cells in spleen of NSG mice were quantified by gating on human CD45+ cells, and a second gate was applied to determine CD19+/CD5+ CLL cells. Representative flow cytometry plots are depicted to the left. The absolute number of CLL cells is significantly decreased in NXT629-treated animals. Data are mean ± SEM. Significant difference: *p < 0.05, unpaired Student t test. n.s., Nonsignificant.Back to article page